Loading
A phase 1/2 trial of Bevacizumab in cervical cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer is a phase 1/2 interventional study registered as NCT07080216 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 120 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-08. Interventions recorded: ZG005, Gecacitinib, Bevacizumab. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Suzhou Zelgen Biopharmaceuticals, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Suzhou Zelgen Biopharmaceuticals, Anti-angiogenic therapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/